From Financial Modeling Prep: 2025-06-05 20:00:00

Precision BioSciences, Inc. is a biotechnology company focused on gene editing technologies for genetic disorders and cancers. The company’s financial efficiency is challenged, with a ROIC of -38.88% and a WACC of 8.61%, resulting in a negative ROIC to WACC ratio of -4.51.

Compared to peers like Homology Medicines and Alector, Precision BioSciences faces similar challenges in generating returns that surpass its cost of capital. Homology Medicines has a ROIC of -48.90% and a WACC of 5.12%, resulting in a ROIC to WACC ratio of -9.55. Alector, Inc. presents a similar situation with a ROIC to WACC ratio of -7.33.

Gossamer Bio, Inc. stands out among its peers with a ROIC to WACC ratio of -2.46, indicating better capital efficiency. This suggests that Gossamer Bio is closer to covering its cost of capital compared to Precision BioSciences, Homology Medicines, and Alector, Inc.



Read more at Financial Modeling Prep:: Precision BioSciences, Inc. (NASDAQ:DTIL) and Its …